Pharmafile Logo

Global ConSeptS – Consultancy

Global ConSeptS – Consultancy is an independent technical consultancy company that was established in 2008. The company specialises in aseptic processing and Quality by Design projects  specific to the global bio-pharmaceutical industry. Our approach is pragmatic and to-the-point. You are our customer and we want you to get the best technical solution rather than a theoretical proposal. Although today Global ConSeptS is a one-man company, we want you to be best served. That is why we closely work together with other competent consultancy companies to provide you the best quality for your projects and assure you on-time delivery.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Company Details

Global Consepts - Europe B.V., Beech Avenue 54, Schiphol-Rijk, NL-1119 PW, Netherlands
+31 (0)20 658 6303

 Latest Content from PMHub 

Data, Evidence, Education: Tackling the Global Multi‑Trillion‑Dollar Rare Disease Burden

Press Releases | February 25, 2026 | Medscape Education

Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when families and caregivers are included. For...

T40: when a number is not just a number

Press Releases | February 23, 2026 | Grace Communications

Proud to be ranked 3rd among the Top 10 UK-focused agencies, along with other categories, Grace Communications finds inspiration in being included in PMLive’s Top 40 Creative Healthcare Agencies 2025.

Why patient engagement must come first in rare disease trials

Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.

New Cuttsy+Cuttsy research shows why site support matters more than ever

Press Releases | February 23, 2026 | Cuttsy + Cuttsy

Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...

#ShortenTheJourney

Press Releases | February 18, 2026 | Medscape Education

For the millions of people living with a rare disease, the path to a diagnosis (if ever received) is often a long and frustrating odyssey. This delay is frequently driven...

Why We Must Stop Normalizing the “Pregnancy Itch”

Press Releases | February 18, 2026 | Medscape Education

In the world of rare diseases, success is often measured by the speed of diagnosis. However, for women facing rare liver conditions like Intrahepatic Cholestasis of Pregnancy (ICP), the medical...

HRW’s Environmental Efforts Recognised with ‘B’ for Transparency by CDP

HRW has been recognised by CDP, the global environmental disclosure organisation, for its commitment to sustainability and environmental transparency. In its first submission to CDP’s SME questionnaire, HRW achieved a...

EpilepsyMeds receives Highly Commended recognition at Excellence in Healthcare Partnership Awards 2026

Press Releases | February 17, 2026 | Genetic Digital

EpilepsyMeds received Highly Commended recognition at the Excellence in Healthcare Partnership Awards 2026, celebrating the collaboration between Desitin Pharma, ChangeMed and Genetic Digital in advancing epilepsy care.